As previously reported, Jefferies upgraded Acadia Healthcare to Buy from Hold with a price target of $30, up from $24.50, citing a belief that new management is well-positioned to bring enhanced operational stability, earnings visibility and "a much-needed boost to underperforming assets." The firm's updated bed build analysis points to about 7% upside to Street EBITDA estimates in FY27 and about 14% upside in FY28, the analyst tells investors.
